Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.58 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59048 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL1901975 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL15435038 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL58338 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL13682227 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL59676 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL15435013 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL59693 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL59443 | 1.00 | TUBB1 (0.58) | TUBB1ELANE | |
| SCHEMBL89669 | 1.00 | TUBB1 (0.58) | TUBB1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881829-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | Eisai Co., Ltd. (JP) | 2008-01-30 | — | — | EP | claimed |
| WO-2006121857-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | EISAI CO., LTD. (JP) | 2006-11-16 | — | — | WO | claimed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1881829-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | Eisai Co., Ltd. (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| WO-2006121857-A2 | UNSOLVATED AND HOST-GUEST SOLVATED CRYSTALLINE FORMS OF (2E,4S)-4-[(N-{[(2R)-1-ISOPROPYLPIPERIDIN-2-YL]-CARBONYL}-3-METHYL-L-VALYL)(METHYL)AMINO]-2,5-DIMETHYLHEX-2-ENOIC ACID AND THEIR PHARMACEUTICAL USES | EISAI CO., LTD. (JP) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | TUBB1 119/4885ELANE 2284/4885 |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885ELANE 4023/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | TUBB1 1668/4885ELANE 4153/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885ELANE 4023/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | TUBB1 436/4885ELANE 4511/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | TUBB1 1157/4885ELANE 3437/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | TUBB1 436/4885ELANE 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.